Hot & Cold Sectors
Tracking the major movements across the best & worst performing industry sector indexes.
Dow 30 Stocks
Top Gainers & Losers
Major Indexes & Stocks to Watch

MORE U.S. INDEXES

» More

TOP HEADLINES

» Markets | Economy | Companies

- Greek Debt Saga Back on Center Stage for Markets

FEATURED SLIDESHOWS

» More

The World's Best Beers
Craft brewers account for only about five percent of the US market, but that may be changing.
Fashion Stocks Traders Love
Over the past couple of months, the “Fast Money” traders weighed in on companies that stood out.
Best in Show
Who is the top dog at the Westminster Kennel Club Dog Show

MOST POPULAR

News

Blog Posts

Videos

SPECIAL REPORTS

» More

- Road Warriors
  All the gadgets and gear a savvy frequent traveler needs to navigate the global economy.

HOT ON FACEBOOK

Stocks Gain Amid China M&A Buzz; GE Rallies

Published: Monday, 14 Sep 2009 | 5:26 PM ET

Text Size

By: Cindy Perman
CNBC.com Staff Writer

Stocks advanced Monday as news that China's sovereign wealth fund is considering a stake in U.S. power company AES helped cool talk about a trade rift between the U.S. and China, which rattled the market earlier.

The Dow Jones Industrial Average rose 21.39 points, or 0.2 percent, to close at 9,629.80. The S&P 500 advanced 0.6 percent and the Nasdaq gained 0.5 percent.

Volatility began to subside in the market: The CBOE volatility index settled below 24.

Major U.S. Indexes

.DJIA

.NCOMP

.SPX

Shares of AES [AES Loading... () ] shot up 4.5 percent, while the S&P utilities index gained 1.4 percent after the Wall Street Journal reported that China and AES were in talks. AES owns 14 utilities, has 11 million customers and $16 billion in annual revenue.

FOR INVESTORS

This was just the latest buzz about M&A activity.

Shares of Sprint Nextel [S Loading... () ] jumped 10 percent following a report in Britain's Sunday Telegraph newspaper that Deutsche Telekom was considering making a bid for the phone carrier. Sources told CNBC that Sprint is not aware of any Deutsche Telekom bid.

Fallout also continued from Kraft's [KFT Loading... () ] failed bid for Cadbury. The British chocolatier released a letter saying the offer failed to reflect the company's true value, and also said Kraft's low-growth conglomerate business model didn't fit in with Cadbury's strategy.

And Johnson & Johnson [JNJ Loading... () ] is in talks to cut the price of its $1.5 billion merger with Irish drugmaker Elan for an 18.4-percent stake in the company and its drug pipeline.

Stocks had started the day lower as a trade dispute between the US and China rattled the market. The rift started on Friday, when President Obama announced tariffs against tires from China, which followed up Monday by asking the World Trade Organization to intervene. The tariffs came on the heels of a union complaint that a surge of imports of the Chinese tires were taking away American jobs.

"You don't want to be messing with your biggest trading partner who holds most of your debt," Joe Saluzzi, co-manager of trading at Themis Trading, told Reuters. The economy "is still teetering on all sorts of edges here. Something like this could be the spark that sends us lower."

General Electric [GE Loading... () ] was the biggest gainer on the Dow, followed by JPMorgan [JPM Loading... () ] and DuPont [DD Loading... () ].

GE shot up more than 4 percent, topping $15 for the first time since January. After breaking through that level, the pace of buying accelerated further.

Banks, including JPMorgan, advanced as they are typically among the biggest beneficiaries of M&A deals.

But Bank of America's [BAC Loading... () ] gain was modest following news that a judge hasrejected its $33 million settlement with the SEC over Merrill Lynch bonuses and several BofA executives face charges over their handling of the deal.

Drug stocks were higher from the getgo as investors took some defensive positions.

Eli Lilly [LLY Loading... () ] rose 1 percent after the drug maker announced plans to cut $1 billion in costs and 5,500 jobs over the next two years. Lilly also backed its full-year non-GAAP forecast of $4.20 to $4.30 a share.

Shares of Salix Pharmaceuticals [SLXP Loading... () ] surged more than 50 percent after the drug maker said its Rifaximin irritable bowl syndrome had met the main goals of late-stage studies.

And Dendreon [DNDN Loading... () ] shares soared 15 percent amid speculation that the company, which is working on a prostate cancer vaccine, is a takeover target.